The chemical class of POLR2J3 inhibitors pertains to molecules that can interact with and inhibit the activity of the POLR2J3 protein, which is a subunit of RNA polymerase II. RNA polymerase II is pivotal for the transcription of DNA into messenger RNA (mRNA) in eukaryotic cells, acting as a bridge in the transfer of genetic information from DNA to RNA, and eventually to protein. The POLR2J3 subunit is part of a larger complex that ensures the accurate transcription of genetic material. Inhibiting POLR2J3, thus, would correspond to altering the functionality of RNA polymerase II. Chemicals within this class would be designed or selected based on their ability to bind to the POLR2J3 subunit, or to the RNA polymerase II complex in a manner that disrupts the function of POLR2J3. The mechanisms of action of these chemicals can be diverse, ranging from competitive inhibition, where the inhibitor competes with the substrate for binding to the active site, to allosteric inhibition, where the inhibitor binds to an alternative site and changes the conformation of the enzyme, making it less effective or inactive.
The structural design of POLR2J3 inhibitors would be heavily influenced by the molecular structure and functional domains of the POLR2J3 protein. Knowledge about the 3D structure of POLR2J3, its interaction sites within the RNA polymerase II complex, and its role in the transcription process would be crucial for the development of effective inhibitors. Besides, the chemical properties such as solubility, stability, and reactivity would also play a vital role in defining the characteristics of this chemical class. The specificity and affinity of these chemicals towards POLR2J3 would dictate their inhibitory potency. The identification and characterization of these inhibitors would require a robust understanding of biochemistry, molecular biology, and chemical biology, intertwining the knowledge from these fields to explore the interaction between these inhibitors and the POLR2J3 subunit or the RNA polymerase II complex.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
Binds directly to RNA polymerase II and inhibits its activity. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
Inhibits the CTD kinase activity of the TFIIH complex, affecting RNA polymerase II phosphorylation and its transcriptional activity. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Intercalates DNA, preventing RNA polymerase movement and thus halting transcription. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Binds to the XPB subunit of the TFIIH complex, impacting RNA polymerase II activity. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Inhibits cyclin-dependent kinases (CDKs) that phosphorylate RNA polymerase II. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $99.00 | 5 | |
Analog of adenosine, terminates mRNA synthesis by RNA polymerase II due to the absence of a hydroxyl group. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Targets BET bromodomains, which are crucial for transcriptional elongation by RNA polymerase II. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $290.00 $5572.00 $10815.00 $25000.00 $65000.00 $2781.00 | 63 | |
Binds to the SF3B1 subunit of the spliceosome, affecting pre-mRNA splicing and thereby RNA polymerase II mediated transcription. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
BTK inhibitor affecting various cellular pathways; its role in RNA polymerase II activity needs further investigation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Kinase inhibitor; its complex interplay with transcriptional regulation potentially affects RNA polymerase II. | ||||||